Funder
Korea Health Industry Development Institute
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Boolell, M. et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 8, 47–52 (1996).
2. Croom, K. F. & Curran, M. P. Sildenafil: a review of its use in pulmonary arterial hypertension. Drugs 68, 383–397 (2008).
3. Henrie, A. M., Nawarskas, J. J. & Anderson, J. R. Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review. Core Evid 10, 99–109,
https://doi.org/10.2147/CE.S58457
(2015).
4. Takimoto, E. et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11, 214–222,
https://doi.org/10.1038/nm1175
(2005).
5. Westermann, D. et al. Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo. Basic Res Cardiol 107, 308,
https://doi.org/10.1007/s00395-012-0308-y
(2012).
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献